CDN1163

CDN1163

Biochem/physiol Actions

CDN1163 treatment declined the hepatic expression of genes implicated in gluconeogenesis and lipogenesis as well as attenuated endoplasmic reticulum (ER) stress response and ER stress-induced apoptosis. CDN1163 interacts with sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) and enhances ER Ca2+ content.

CDN1163 is an allosteric activator of sarco/ endoplasmic reticulum Ca2+-ATPase (SERCA) that potently lowered fasting blood glucose, improved glucose tolerance and ameliorated hepatosteatosis in ob/ob mice. Additionally CDN1163 induces significant reduction in adipose tissue weight with no change in lean mass in ob/ob mice. CDN1163 has no effect on glucose levels or body weight in lean control mice.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3575260 CDN1163 white to beige 100 GVGVYDCVFBGALZ-UHFFFAOYSA-N 1S/C20H20N2O2/c1-13(2)24-17-11-9-16(10-12-17)20(23)22-18-6-4-5-15-8-7-14(3)21-19(15)18/h4-13H,1-3H3,(H,22,23)
£456.86 (exc VAT) per 25MG
-
+
3575261 CDN1163 white to beige 100 GVGVYDCVFBGALZ-UHFFFAOYSA-N 1S/C20H20N2O2/c1-13(2)24-17-11-9-16(10-12-17)20(23)22-18-6-4-5-15-8-7-14(3)21-19(15)18/h4-13H,1-3H3,(H,22,23)
£140.68 (exc VAT) per 5MG
-
+